Literature DB >> 3295018

Randomized trial of portacaval shunt, stapling transection and endoscopic sclerotherapy in uncontrolled variceal bleeding.

J Terés, R Baroni, J M Bordas, J Visa, C Pera, J Rodés.   

Abstract

Seventy consecutive cirrhotic patients with persistent or recurrent variceal bleeding were included in a clinical trial to compare the efficacy and safety of portacaval shunt (PCS) and stapler transection (ST) in patients with low surgical risk, and of stapler transection and endoscopic sclerotherapy (ES) in patients with high surgical risk. To classify the patients into low- and high-risk groups a new scoring system was used, based on an analysis of factors influencing operative mortality in an earlier series of emergency portacaval shunt. Thirty-eight low-risk patients were randomly allocated for treatment with portacaval shunt (19 patients) or stapler transection (19 patients), and 32 high-risk patients for stapler transection (17 patients) or ES (15 patients). The operative mortality of patients treated by PCS was close to that expected according to retrospective data, this indicating that the proposed scoring system is highly discriminant. In low-risk patients, portacaval shunt evidenced greater haemostatic efficacy and fewer complications than stapler transection. However, hepatic encephalopathy during follow-up was more frequent in the portacaval shunt group and there were no significant differences in operative mortality and long-term survival between the two groups. In high-risk patients, stapler transection and sclerotherapy had a similar haemostatic efficacy, operative mortality and long-term survival. However, sclerotherapy occasioned fewer complications than stapler transection. Our results motivate us to recommend stapler transection for low-risk patients and to consider sclerotherapy as an alternative for high-risk patients in the emergency treatment of uncontrolled variceal bleeding.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3295018     DOI: 10.1016/s0168-8278(87)80075-2

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  20 in total

1.  UK guidelines on the management of variceal haemorrhage in cirrhotic patients. British Society of Gastroenterology.

Authors:  R Jalan; P C Hayes
Journal:  Gut       Date:  2000-06       Impact factor: 23.059

Review 2.  Acute variceal bleeding: general management.

Authors:  D Patch; L Dagher
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

Review 3.  Historical overview and review of current day treatment in the management of acute variceal haemorrhage.

Authors:  Neil Rajoriya; Dhiraj Tripathi
Journal:  World J Gastroenterol       Date:  2014-06-07       Impact factor: 5.742

4.  Treatment of portal hypertension by subtotal splenectomy and central splenorenal shunt.

Authors:  A Petroianu
Journal:  Postgrad Med J       Date:  1988-01       Impact factor: 2.401

Review 5.  Portosystemic shunts versus endoscopic therapy for variceal rebleeding in patients with cirrhosis.

Authors:  S Khan; C Tudur Smith; P Williamson; R Sutton
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18

Review 6.  Experience with radical esophagogastric devascularization procedures (Sugiura) for variceal bleeding outside Japan.

Authors:  M Dagenais; B Langer; B R Taylor; P D Greig
Journal:  World J Surg       Date:  1994 Mar-Apr       Impact factor: 3.352

Review 7.  Surgical management of portal hypertension.

Authors:  J C Collins; I J Sarfeh
Journal:  West J Med       Date:  1995-06

Review 8.  Acute management of bleeding oesophageal varices.

Authors:  A K Burroughs
Journal:  Drugs       Date:  1992       Impact factor: 9.546

9.  [Therapy of bleeding esophageal varices in West Germany--results of a survey].

Authors:  K W Steegmüller; D Schmidt; T Junginger
Journal:  Langenbecks Arch Chir       Date:  1991

Review 10.  Portal hypertension and gastrointestinal bleeding: diagnosis, prevention and management.

Authors:  Erwin Biecker
Journal:  World J Gastroenterol       Date:  2013-08-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.